MicroPhage Inc has reached an agreement with Cardinal Health granting exclusive rights to market the KeyPath MRSA/MSSA Blood Culture Test product line in North America. Under the agreement, Cardinal Health will gain the exclusive distribution rights to the recently 510(k)-cleared KeyPath MRSA/MSSA Blood Culture Test – BT and other products in development for testing blood culture specimens for Staphylococcus aureus, in the US, Canada, and US territories. In exchange for these rights, Cardinal Health has provided MicroPhage with operational funding for development and commercialization of new products.

The KeyPath MRSA/MSSA Blood Culture Test – BT provides same-day antibiotic susceptibility and resistance results for these deadly infections. In a previously released statement, Alberto Gutierrez, PhD, director of the Office of In Vitro Diagnostics Device Evaluation and Safety in the FDA’s Center for Devices and Radiological Health said, “Clearing this test gives health care professionals a test that can confirm S. aureus and then identify whether the bacteria is MRSA or MSSA. This not only saves time in diagnosing potentially life-threatening infections but also allows health care professionals to optimize treatment and start appropriate contact precautions to prevent the spread of the organism.”

Source: MicroPhage Inc